Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials

Cardiovascular risk reduction with liraglutide and semaglutide in patients with type 2 diabetes was demonstrated in the LEADER (ClinicalTrials.gov: NCT01179048) and SUSTAIN 6 (ClinicalTrials.gov: NCT01720446) cardiovascular outcome trials. This post hoc analysis assessed the impact of diabetes durat...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Subodh, Bain, Stephen C., Monk Fries, Tea, Mazer, C. David, Nauck, Michael A., Pratley, Richard E., Rasmussen, Søren, Saevereid, Hans A., Zinman, Bernard, Buse, John B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619033/
https://www.ncbi.nlm.nih.gov/pubmed/30851070
http://dx.doi.org/10.1111/dom.13698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619033/
https://www.ncbi.nlm.nih.gov/pubmed/30851070
http://dx.doi.org/10.1111/dom.13698

Ejemplares similares